BillionToOne, Inc.

BLLN Healthcare Diagnostics & Research

BillionToOne, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $305.1 million, up 100.0% from fiscal 2024.

Revenue
+47.2%
EPS
+164.3%
Free cash flow
+9.25%
Total debt
+60.6%

Quarter to September 2026, against a year earlier

111.96 1.93 −1.69%
Market cap
$5.3B
P/E
88.7×
Fwd P/E
146×
Dividend yield
—
F-score
n/a
Altman Z
6.04
Beneish M
−2.03
Dividend safety
n/a

BillionToOne, Inc. (BLLN) P/E ratio

Alert me on P/E ratio

As of 5 November 2026, BillionToOne, Inc. (BLLN) trades at a P/E ratio of 88.7×. Over the past ten years it has ranged from 0.0× (December 2025) to 1,599× (January 2026); the current reading is higher than 25% of that period. That is above the Diagnostics & Research industry median of 34.5× and above the Healthcare sector median of 25.2×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 1,320× —
FY2024 0.0× —
FY2023 0.0× —

Quarterly newest first

Period P/E ratio Change
Sep 2026 84.3× (27.45%)
Jun 2026 116× 23.47%
Mar 2026 94.1× (92.87%)
Dec 2025 1,320× —
4 more quarters

Against its own ten years

Low 0.0× High 1,599×
Ten-year median 105×
Current reading's percentile 25

P/E ratio against peers

Company P/E ratio
RDNT RadNet, Inc. compare n/m
NEO NeoGenomics, Inc. compare n/m
GRAL GRAIL, Inc. compare n/m
ADPT Adaptive Biotechnologies Corporation compare n/m
VCYT Veracyte, Inc. compare 15.2×
QGEN QIAGEN N.V. compare 26.1×
SHC Sotera Health Company compare 26.3×
CDNA CareDx, Inc. compare 30.9×
BLLN BillionToOne, Inc. 88.7×
Diagnostics & Research industry median 34.5×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on BLLN